NGM Biopharmaceuticals Inc.’s Initial Public Offering

Davis Polk advised the underwriters in connection with an initial public offering of 6,666,667 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds of $106.7 million.

Concurrent with the public offering, Merck Sharp & Dohme Corp. purchased 4,121,683 shares of NGM common stock in a separate private placement, resulting in additional gross proceeds of $65.9 million.

The common stock is listed on the Nasdaq Global Select Market under the symbol “NGM.”

Goldman Sachs & Co. LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC acted as underwriters on the deal.

Headquartered in South San Francisco, California, NGM is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.

The Davis Polk corporate team included partners Bruce K. Dallas (Picture) and Sarah K. Solum and associates Donald K. Lang, Beth LeBow and Blake Anderson. Partner David R. Bauer and associate Jay Frankel provided intellectual property and technology advice. The tax team included partner Rachel D. Kleinberg and associate Rebecca A. Rosen. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Blake Anderson – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Bruce Dallas – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Donald Lang – Davis Polk & Wardwell; Beth LeBow – Davis Polk & Wardwell; Rebecca Rosen – Davis Polk & Wardwell; Sarah K. Solum – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Citigroup Global Markets Ltd; Cowen and Company; Goldman Sachs & Co.;


Author: Ambrogio Visconti